A recent research study has found that childhood obesity is more common now than 12 years ago – which is particularly troubling news, given that obesity increases the risk of insulin resistance and Type 2 diabetes.
However, the FDA has recently approved Qsymia for treatment of obesity for adolescents (ages 12-17), following a clinical trial for Qsymia, which found more than 44% of adolescent patients lost at least 15% of their body weight and more than 30% of patients lost at least 20% of their body weight.
To read more, CLICK HERE.
